Open AccessSequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer
Author(s) -
А. В. Султанбаев,
А. Ф. Насретдинов,
Н. И. Султанбаева,
К. V. Menshikov,
Ш. И. Мусин,
А. А. Измайлов,
Oleg Lipatov,
В. А. Пушкарев,
Р. Б. Валиахмедов,
А. В. Пушкарев,
Ф. Ф. Муфазалов
Publication year - 2021
Publication title -
zlokačestvennye opuholi
Language(s) - English
Resource type - Journals
eISSN - 2587-6813
pISSN - 2224-5057
DOI - 10.18027/2224-5057-2020-10-3
Subject(s) - medicine , breast cancer , metastatic breast cancer , cancer , disease , oncology , hormone receptor , primary tumor , hormone therapy , hormone , metastasis
Breast cancer (BC) is a heterogeneous disease characterized by the presence or absence of membrane receptor overexpression on tumor cells that correlates with the disease prognosis. Understanding of the patterns and mechanisms of tumor progression gained through clinical experience of managing BC patients is important. The treatment strategy depends on the hormone receptor status of the tumor, the HER2 / neu expression, and the proliferative activity level. A clinical case of advanced luminal A breast cancer is reported, and the rationale for sequential treatment strategy is provided taking into account the clinical situation and clinical course of the disease. Adequate endocrine therapy for hormone-positive metastatic BC provides long-term tumor control like in this case, as well as a high quality of life over the entire course of sequential treatment with anticancer drugs.